Larimar Therapeutics (LRMR) EBT (2013 - 2026)
Larimar Therapeutics' (LRMR) quarterly EBT came in at -$64.0 million in Q4 2025, down 104.54% YoY from $1.4 billion in Q4 2024, and down 26.36% on a QoQ basis from -$50.7 million in Q3 2025.
Larimar Therapeutics (LRMR) EBT (2013 - 2026) Analysis & Trends
Larimar Therapeutics (LRMR) has 13 years of EBT data on file, last reported at -$64.0 million in Q4 2025.
- Quarterly EBT fell 104.54% year-over-year to -$64.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$181.0 million (down 51.92% YoY) and the FY2025 annual result came in at -$174.0 million, up 34.07% from the prior year.
- EBT eased to -$64.0 million in Q4 2025, from -$50.7 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$9.7 million in Q1 2023 to a low of -$155.9 million in Q4 2023.
- A 5-year average of -$43.9 million and a median of -$26.7 million in 2024 frame the typical range for EBT.
- The widest YoY moves for EBT: up 79.92% in 2024, down 186.01% in 2024.
- Tracing LRMR's EBT over 5 years: stood at -$133.1 million in 2021, then fell by 6.14% to -$141.3 million in 2022, then declined by 10.38% to -$155.9 million in 2023, then surged by 79.92% to -$31.3 million in 2024, then plunged by 104.54% to -$64.0 million in 2025.
- The last three EBT figures came in at -$64.0 million (Q4 2025), -$50.7 million (Q3 2025), and -$29.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Larimar Therapeutics | 452.93 Mn | 296.66 Mn | - | -40.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.28 Mn |
| Dec 31, 2025 | -64.05 Mn |
| Sep 30, 2025 | -50.69 Mn |
| Jun 30, 2025 | -28.98 Mn |
| Mar 31, 2025 | -37.24 Mn |
| Dec 31, 2024 | -31.31 Mn |
| Sep 30, 2024 | -25.66 Mn |
| Jun 30, 2024 | -34.40 Mn |
| Mar 31, 2024 | -27.73 Mn |
| Dec 31, 2023 | -155.93 Mn |
| Sep 30, 2023 | -17.60 Mn |
| Jun 30, 2023 | -16.62 Mn |
| Mar 31, 2023 | -9.70 Mn |
| Dec 31, 2022 | -141.27 Mn |
| Sep 30, 2022 | -10.86 Mn |
| Jun 30, 2022 | -11.18 Mn |
| Mar 31, 2022 | -17.39 Mn |
| Dec 31, 2021 | -133.10 Mn |
| Sep 30, 2021 | -19.69 Mn |
| Jun 30, 2021 | -21.94 Mn |